Veristat, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Southborough MA United States (1994)

Organization Overview

First Clinical Trial
2011
NCT01433731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Veristat | Veristat, Inc. | Veristat, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 1)

Cerebellar Ataxia (Phase 1)

Communicable Diseases (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Friedreich Ataxia (Phase 1)

Hypertension (Phase 2)

Infections (Phase 3)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Migraine Disorders (Phase 2)

Osteoarthritis (Phase 2)

Parkinson Disease (Phase 1)

Prehypertension (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 18